Unknown

Dataset Information

0

Preventing olanzapine-induced weight gain using betahistine: a study in a rat model with chronic olanzapine treatment.


ABSTRACT: Olanzapine is the one of first line antipsychotic drug for schizophrenia and other serious mental illness. However, it is associated with troublesome metabolic side-effects, particularly body weight gain and obesity. The antagonistic affinity to histamine H1 receptors (H1R) of antipsychotic drugs has been identified as one of the main contributors to weight gain/obesity side-effects. Our previous study showed that a short term (2 weeks) combination treatment of betahistine (an H1R agonist and H3R antagonist) and olanzapine (O+B) reduced (-45%) body weight gain induced by olanzapine in drug-naïve rats. A key issue is that clinical patients suffering with schizophrenia, bipolar disease and other mental disorders often face chronic, even life-time, antipsychotic treatment, in which they have often had previous antipsychotic exposure. Therefore, we investigated the effects of chronic O+B co-treatment in controlling body weight in female rats with chronic and repeated exposure of olanzapine. The results showed that co-administration of olanzapine (3 mg/kg, t.i.d.) and betahistine (9.6 mg/kg, t.i.d.) significantly reduced (-51.4%) weight gain induced by olanzapine. Co-treatment of O+B also led to a decrease in feeding efficiency, liver and fat mass. Consistently, the olanzapine-only treatment increased hypothalamic H1R protein levels, as well as hypothalamic pAMPK?, AMPK? and NPY protein levels, while reducing the hypothalamic POMC, and UCP1 and PGC-1? protein levels in brown adipose tissue (BAT). The olanzapine induced changes in hypothalamic H1R, pAMPK?, BAT UCP1 and PGC-1? could be reversed by co-treatment of O+B. These results supported further clinical trials to test the effectiveness of co-treatment of O+B for controlling weight gain/obesity side-effects in schizophrenia with chronic antipsychotic treatment.

SUBMITTER: Lian J 

PROVIDER: S-EPMC4118967 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature

altmetric image

Publications

Preventing olanzapine-induced weight gain using betahistine: a study in a rat model with chronic olanzapine treatment.

Lian Jiamei J   Huang Xu-Feng XF   Pai Nagesh N   Deng Chao C  

PloS one 20140801 8


Olanzapine is the one of first line antipsychotic drug for schizophrenia and other serious mental illness. However, it is associated with troublesome metabolic side-effects, particularly body weight gain and obesity. The antagonistic affinity to histamine H1 receptors (H1R) of antipsychotic drugs has been identified as one of the main contributors to weight gain/obesity side-effects. Our previous study showed that a short term (2 weeks) combination treatment of betahistine (an H1R agonist and H3  ...[more]

Similar Datasets

| S-EPMC3965561 | biostudies-literature
| S-EPMC6277778 | biostudies-literature
| S-EPMC5911481 | biostudies-literature
| S-EPMC6764014 | biostudies-literature
| S-EPMC7256453 | biostudies-literature
| S-EPMC5669575 | biostudies-literature